Anlotinib and irinotecan for advanced Ewing sarcoma after failure of standard therapy: A multicenter, two-cohort, single-arm, open label, phase Ib/II trial (NCT03416517).

被引：0
|
作者：
Xu, Jie
Xie, Lu
Guo, Wei
Tang, Xiaodong
Yang, Rongli
Yan, Taiqiang
Liu, Kuisheng
Gu, Jin
机构：
[1] Peking Univ, Peoples Hosp, Beijing, Peoples R China
[2] Peking Univ, Canc Hosp, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11012
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Anlotinib, Vincristine, and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy: A Two-Cohort, Phase Ib/II Trial
    Xu, Jie
    Xie, Lu
    Sun, Xin
    Liu, Kuisheng
    Tang, Xiaodong
    Yan, Taiqiang
    Yang, Rongli
    Guo, Wei
    Gu, Jin
    ONCOLOGIST, 2021, 26 (07): : E1256 - E1262
  • [2] Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
    Tawbi, Hussein A.
    Burgess, Melissa
    Bolejack, Vanessa
    Van Tine, Brian A.
    Schuetze, Scott M.
    Hu, James
    D'Angelo, Sandra
    Attia, Steven
    Riedel, Richard F.
    Priebat, Dennis A.
    Movva, Sujana
    Davis, Lara E.
    Okuno, Scott H.
    Reed, Damon R.
    Crowley, John
    Butterfield, Lisa H.
    Salazar, Ruth
    Rodriguez-Canales, Jaime
    Lazar, Alexander J.
    Wistuba, Ignacio I.
    Baker, Laurence H.
    Maki, Robert G.
    Reinke, Denise
    Patel, Shreyaskumar
    LANCET ONCOLOGY, 2017, 18 (11): : 1493 - 1501
  • [3] Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial
    Xu, Jianming
    Li, Jie
    Bai, Chunmei
    Xu, Nong
    Zhou, Zhiwei
    Li, Zhiping
    Zhou, Caicun
    Jia, Ru
    Lu, Ming
    Cheng, Yuejuan
    Mao, Chenyu
    Wang, Wei
    Cheng, Ke
    Su, Chunxia
    Hua, Ye
    Qi, Chuan
    Li, Jing
    Wang, Wei
    Li, Ke
    Sun, Qiaoling
    Ren, Yongxin
    Su, Weiguo
    CLINICAL CANCER RESEARCH, 2019, 25 (12) : 3486 - 3494
  • [4] Anlotinib in Chinese Patients With Recurrent Advanced Cervical Cancer: A Prospective Single-Arm, Open-Label Phase II Trial
    Zhu, Jun
    Song, Chunyan
    Zheng, Zhong
    Xia, Lingfang
    Chen, Yanqiong
    Ke, Guihao
    Wu, Xiaohua
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [5] Anlotinib plus Epirubicin Followed by Anlotinib Maintenance as First-line Treatment for Advanced Soft-tissue Sarcoma: An Open-label, Single-arm, Phase II Trial
    Wang, Zhi-ming
    Zhuang, Rong-yuan
    Guo, Xi
    Zhang, Chen-lu
    You, Yang
    Chen, Li-sha
    Liu, Wen-shuai
    Zhang, Yong
    Luo, Rong-kui
    Hou, Ying-yong
    Lu, Wei-qi
    Zhou, Yu-hong
    CLINICAL CANCER RESEARCH, 2022, 28 (24) : 5290 - 5296
  • [6] Efficacy and safety of apatinib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib: An open-label, multicenter, single-arm, phase II trial
    Cai, Z.
    Zhang, B.
    Yin, Y.
    Cao, D.
    ANNALS OF ONCOLOGY, 2019, 30 : 698 - 698
  • [7] Anlotinib in combination with TQB2450 in patients with recurrent ovarian cancer (ACTION): A multicenter, single-arm, open-label, phase Ib trial.
    Lan, Chunyan
    Zhao, Jing
    Yang, Fan
    Li, Rong
    Huang, Yu
    Wang, Jing
    Zhao, Weihong
    Zhang, Li
    Liu, Chang
    Bi, Xuehan
    Jin, Haihong
    Meng, Jin
    Huang, Xin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial (vol 18, pg 1493, 2017)
    Tawbi, H. A.
    Burgess, M.
    Bolejack, V
    LANCET ONCOLOGY, 2018, 19 (01): : E8 - E8
  • [9] Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial (vol 18, pg 1493, 2017)
    Tawbi, H. A.
    Burgess, M.
    Bolejack, V
    LANCET ONCOLOGY, 2017, 18 (12): : E711 - E711
  • [10] Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial
    Wei, W.
    Ban, X.
    Yang, F.
    Huang, Y.
    Li, J.
    Cheng, X.
    Zheng, M.
    Li, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S762 - S762
12345